Articles related to HEMATOLOGIC MALIGNANCIES
Multiple Myeloma with Manni Mohyuddin, MD
Dr. Mohyudding summarizes key findings ASCO reports, including updates on teclistamab in CAR-T, the DETERMINATION trial assessing auto-transplantation, cilta-cel (covered by HCN here), and the ATLAS study evaluating carfilzomib with lenalidomide and dexamethasone as maintenance vs. lenalidomide alone.
Oncology, Medical June 21st 2022
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
This report provides longer-term results from the CARTITUDE-1 trial of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma. This update covers 97 patients at a median follow up of ~28 months. The overall response rate was 97.9%, with an 82% stringent complete response across both standard and high-risk subgroups. These longer-term data from CARTITUDE-1 in triple-class exposed patients with RRMM demonstrate deep and durable responses to cilta-cel over time, including in high-risk subgroups.
Oncology, Medical June 21st 2022
CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL): A Comprehensive Review
CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.
Oncology, Medical May 25th 2022
FDA Advisory Panel Calls for Randomized Data for PI3K Inhibitor Approvals for Blood Cancers
An FDA expert panel voted 16-0, with one abstention, recommending that future FDA approvals of PI3K inhibitors be supported by randomized data. The four currently-approved PI3K inhibitors for treating hematologic malignancies received FDA approval based on single-arm data. Although these drugs have offered durable ORR and improvements in PFS, randomized data presented at the hearing showed they are associated with higher rates of serious adverse events, including fatality.
Oncology, Medical April 26th 2022
Molecular Characterization of Mutant TP53 Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
In an integrated analysis of mutations and clinical outcomes, comprising 2,200 patients with TP53-mutated myelodysplastic syndrome (MDS) with excess blasts (EB) or TP53-mutated acute myeloid leukemia (AML), the authors state that mutant TP53 AML and MDS-EB “do not differ with respect to molecular characteristics and survival” and argue these entities should be considered a single molecular disease entity. In a commentary to the above paper, TP53 and the star-crossed lovers MDS and AML, John Welch, MD, PhD of Washington University School of Medicine writes, “As a junior Hematology/Oncology fellow, I was told there were two types of physicians: splitters and mergers. That is, clinicians either seek to diagnose increasingly homogenously narrow groups of patients based on increasingly refined, shared characteristics, or they seek to find broad, overarching patterns that unite diagnostic classifications. Hematologic malignancies have been fertile ground for the diagnostic splitters of the world. On the other hand, there have been some noteworthy exceptions. Sometimes it is a technological advance that allows for the synthesis of disparate diagnoses.”
Hematology April 19th 2022
Guiding the Global Evolution of Cytogenetic Testing for Hematologic Malignancies
This international consortium of oncologists and researcher describe the advantages and limitations of both conventional chromosome banding and novel sequencing technologies. They state, “While one single test may not replace the totality of tests that currently exist, the active exploration and adoption of novel approaches in defined clinical settings may indeed allow for a continued and controlled evolution resulting in the successful clinical implementation of whole genome sequencing in the near future.”
Oncology, Medical April 19th 2022